Evidence map›Paper›PMID 26197361›Full record

ReviewProgress in retinal and eye research2015

Progress in corneal wound healing.

Alexander V Ljubimov, Mehrnoosh Saghizadeh

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in Progress in retinal and eye research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03653650 (Autologous Platelet-rich Plasma in the Treatment of Persistent Corneal Epithelial Defects), which is not on this map. Cited by 472 papers.

0numbers the graph read from it
0cells of the map it votes in
472citing papers in PubMed
30.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03653650 narecruitingnot on this mapstarted 2018, after this paper: background citation

Autologous Platelet-rich Plasma in the Treatment of Persistent Corneal Epithelial Defects

TypeinterventionalSponsorUniversidad Autonoma de Nuevo LeonRan2018 to 2027Enrolled54ConditionsPersistent Epithelial DefectArmsPRP plus BCL, BCL plus PFL, Eye patch plus ocular lubricant ointment
3 · Its place in the literature

Who cites it

472 citing papers in PubMed, 831 citations in OpenAlex.

  1. Peripheral nodulocystic corneal degeneration: a case report.American journal of ophthalmology case reports · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

412 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Alexander V LjubimovEye Program, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurosurgery, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA. Electronic address: ljubimov@cshs.org.
Mehrnoosh SaghizadehEye Program, Board of Governors Regenerative Medicine Institute, Departments of Biomedical Sciences and Neurosurgery, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USRegenerative Medicine Institute · MX

Funding

Mechanisms of Epithelial Alterations in Diabetic CorneaR01EY013431 · NEI · CEDARS-SINAI MEDICAL CENTER · PI Alexander V Ljubimov · 2001 to 2026
$11.3M
The Role of MicroRNAs in Normal and Diseased Corneal Epithelial HomeostasisR01EY025377 · NEI · CEDARS-SINAI MEDICAL CENTER · PI Mehrnoosh Saghizadeh Ghiam · 2015 to 2026
$4.3M
Transplantable limbal cells from induced pluripotent stem cellsR01EY023429 · NEI · CEDARS-SINAI MEDICAL CENTER · PI LJUBIMOV, ALEXANDER V · 2013 to 2015
$1.2M
The Role and Mechanisms of microRNAs in Diabetic CorneaR21EY022771 · NEI · CEDARS-SINAI MEDICAL CENTER · PI GHIAM, MEHRNOOSH SAGHIZADEH · 2012 to 2013
$443k
NEI NIH HHS R01 EY013431NEI NIH HHS R01 EY023429NEI NIH HHS R01 EY025377NEI NIH HHS R01 EY13431NEI NIH HHS R21 EY022771
6 · The paper itself

Abstract

Corneal wound healing is a complex process involving cell death, migration, proliferation, differentiation, and extracellular matrix remodeling. Many similarities are observed in the healing processes of corneal epithelial, stromal and endothelial cells, as well as cell-specific differences. Corneal epithelial healing largely depends on limbal stem cells and remodeling of the basement membrane. During stromal healing, keratocytes get transformed to motile and contractile myofibroblasts largely due to activation of transforming growth factor-β (TGF-β) system. Endothelial cells heal mostly by migration and spreading, with cell proliferation playing a secondary role. In the last decade, many aspects of wound healing process in different parts of the cornea have been elucidated, and some new therapeutic approaches have emerged. The concept of limbal stem cells received rigorous experimental corroboration, with new markers uncovered and new treatment options including gene and microRNA therapy tested in experimental systems. Transplantation of limbal stem cell-enriched cultures for efficient re-epithelialization in stem cell deficiency and corneal injuries has become reality in clinical setting. Mediators and course of events during stromal healing have been detailed, and new treatment regimens including gene (decorin) and stem cell therapy for excessive healing have been designed. This is a very important advance given the popularity of various refractive surgeries entailing stromal wound healing. Successful surgical ways of replacing the diseased endothelium have been clinically tested, and new approaches to accelerate endothelial healing and suppress endothelial-mesenchymal transformation have been proposed including Rho kinase (ROCK) inhibitor eye drops and gene therapy to activate TGF-β inhibitor SMAD7. Promising new technologies with potential for corneal wound healing manipulation including microRNA, induced pluripotent stem cells to generate corneal epithelium, and nanocarriers for corneal drug delivery are discussed. Attention is also paid to problems in wound healing understanding and treatment, such as lack of specific epithelial stem cell markers, reliable identification of stem cells, efficient prevention of haze and stromal scar formation, lack of data on wound regulating microRNAs in keratocytes and endothelial cells, as well as virtual lack of targeted systems for drug and gene delivery to select corneal cells.

Indexed as

Corneal InjuriesAnimalsCorneaCorneal Endothelial Cell LossCorneal StromaCytokinesEnzyme InhibitorsEpithelium, CornealGenetic TherapyHumansIntercellular Signaling Peptides and ProteinsMicroRNAsrho-Associated KinasesSignal TransductionStem Cell TransplantationWound HealingCytokinesEnzyme InhibitorsIntercellular Signaling Peptides and ProteinsMicroRNAsrho-Associated KinasesCorneal endotheliumCorneal epitheliumGene therapyKeratocyteStem cellWound healing

Identifiers

PMID26197361
PMCPMC4651844
OpenAlexW936257692

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.